These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29441972)

  • 21. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.
    Matsumoto K; Abematsu K; Shigemi A; Kanazawa N; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    J Chemother; 2016 Jun; 28(3):198-202. PubMed ID: 26187373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.
    Candoni A; Caira M; Cesaro S; Busca A; Giacchino M; Fanci R; Delia M; Nosari A; Bonini A; Cattaneo C; Melillo L; Caramatti C; Milone G; Scime' R; Picardi M; Fanin R; Pagano L;
    Mycoses; 2014 Jun; 57(6):342-50. PubMed ID: 24373120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of monitoring plasma concentration of voriconazole in a patient with liver failure: A case report.
    Liu X; Su H; Tong J; Chen J; Yang H; Xiao L; Hu J; Zhang L
    Medicine (Baltimore); 2017 Oct; 96(42):e8039. PubMed ID: 29049191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.
    Jin H; Wang T; Falcione BA; Olsen KM; Chen K; Tang H; Hui J; Zhai S
    J Antimicrob Chemother; 2016 Jul; 71(7):1772-85. PubMed ID: 26968880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin
.
    Hirata A; Noto K; Ota R; Yokoyama S; Hosomi K; Takada M; Matsuoka H
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):135-143. PubMed ID: 30686290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes.
    Niioka T; Fujishima N; Abumiya M; Yamashita T; Ubukawa K; Nara M; Fujishima M; Takahashi N; Miura M
    Ther Drug Monit; 2017 Oct; 39(5):514-521. PubMed ID: 28834922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.
    Neofytos D; Ostrander D; Shoham S; Laverdiere M; Hiemenz J; Nguyen H; Clarke W; Brass L; Lu N; Marr KA
    Transpl Infect Dis; 2015 Dec; 17(6):831-7. PubMed ID: 26346408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of voriconazole therapeutic drug monitoring: a meta-analysis.
    Luong ML; Al-Dabbagh M; Groll AH; Racil Z; Nannya Y; Mitsani D; Husain S
    J Antimicrob Chemother; 2016 Jul; 71(7):1786-99. PubMed ID: 27165788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Scedosporium apiospermum infectious scleritis following posterior subtenon triamcinolone acetonide injection: a case report and literature review.
    Todokoro D; Hoshino J; Yo A; Makimura K; Hirato J; Akiyama H
    BMC Ophthalmol; 2018 Feb; 18(1):40. PubMed ID: 29433463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
    Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential voriconazole associated posterior reversible leukoencephalopathy in children with malignancies: Report of two cases.
    Amanati A; Lotfi M; Manen RV; Faghihi MA; Yavarian M; Zekavat O; Badiee P; Mazinani NH; Bozorgi H
    J Oncol Pharm Pract; 2021 Mar; 27(2):498-504. PubMed ID: 32689868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
    Trubiano JA; Crowe A; Worth LJ; Thursky KA; Slavin MA
    J Antimicrob Chemother; 2015 Apr; 70(4):1161-5. PubMed ID: 25558073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infantile Aspergillus fumigatus ventriculitis successfully treated with monitoring of plasma and cerebrospinal fluid voriconazole concentration level.
    Furudate A; Hirose S; Abe K; Kawashima A; Hashimoto K; Yamazaki S; Kamei K; Ishiwada N; Hamada H; Sato M
    J Infect Chemother; 2020 Jan; 26(1):132-135. PubMed ID: 31350185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macular toxicity and blind spot enlargement during a treatment by voriconazole: A case report.
    Mounier A; Agard E; Douma I; Chehab HE; Vie AL; Dot JM; Dot C
    Eur J Ophthalmol; 2018 Jul; 28(4):NP11-NP14. PubMed ID: 29623723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors associated with insufficient and potentially toxic voriconazole plasma concentrations: an observational study.
    Wei X; Zhao M; Fu P; Xiao X
    J Chemother; 2019; 31(7-8):401-407. PubMed ID: 31359851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
    Safdar A; Rodriguez GH; Lichtiger B; Dickey BF; Kontoyiannis DP; Freireich EJ; Shpall EJ; Raad II; Kantarjian HM; Champlin RE
    Cancer; 2006 Jun; 106(12):2664-71. PubMed ID: 16691620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring.
    Imhof A; Schaer DJ; Schanz U; Schwarz U
    Swiss Med Wkly; 2006 Nov; 136(45-46):739-42. PubMed ID: 17183438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms.
    Zeng G; Wang L; Shi L; Li H; Zhu M; Luo J; Zhang Z
    Eur J Clin Pharmacol; 2020 Apr; 76(4):515-523. PubMed ID: 31932875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment of Beauveria bassiana fungal keratitis with topical voriconazole.
    Ogawa A; Matsumoto Y; Yaguchi T; Shimmura S; Tsubota K
    J Infect Chemother; 2016 Apr; 22(4):257-60. PubMed ID: 26603426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.